22:45 , Jul 19, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 10 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Six-month EPS Company Date Pre/post mkt 2Q19...
23:58 , Jul 15, 2019 |  BC Extra  |  Clinical News

Neon points to PFS, biomarkers as signs of neoantigen activity in single-arm combo trial

With Phase Ib data on its neoantigen cancer vaccine plus Opdivo announced Monday, Neon is the latest company to suggest its immuno-oncology candidate improves on the efficacy of checkpoint inhibitor alone by comparing a single-arm...
23:36 , Jul 15, 2019 |  BC Extra  |  Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma...
01:30 , Jul 13, 2019 |  BioCentury  |  Tools & Techniques

Broadening role for external control arms in clinical trials

External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between...
20:45 , Jul 11, 2019 |  BC Extra  |  Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc....
23:56 , Jul 8, 2019 |  BC Extra  |  Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...
22:00 , Jul 3, 2019 |  BC Extra  |  Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
23:40 , Jul 2, 2019 |  BC Extra  |  Company News

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb

Having gained rights to Incyte’s PD-1 inhibitor, Zai rolled out an immuno-oncology combination strategy it thinks can carve out a space in the crowded Chinese checkpoint inhibitor field. Zai Lab Ltd. (NASDAQ:ZLAB) licensed exclusive rights...
00:18 , Jul 2, 2019 |  BC Extra  |  Company News

Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...